Source Count: 14 | Weighted Score: 35 | Source Confidence: [4/5] | Primary Tier: 2 | Last Updated: April 10, 2026
Keywords: ibogaine, iboga, Tabernanthe iboga, addiction, opioid, noribogaine, GDNF, neuroplasticity, Bwiti, anti-addictive, Howard Lotsof, kappa opioid, NMDA, serotonin, cardiac risk, 18-MC
Category Tags: ibogaine, addiction-treatment, psychedelic, pharmacology, neuroscience
Cross-References: Y_1_01 — Psychedelics Overview · X_4_15 — Addiction Medicine · K_1_02 — Consciousness Neuroscience

QUICK SUMMARY

Ibogaine — a naturally occurring psychoactive indole alkaloid extracted from the root bark of Tabernanthe iboga, a shrub native to the equatorial forests of Gabon and Cameroon — has emerged as one of the most pharmacologically unique and controversial substances in addiction medicine, with dramatic but clinically complex potential. KEY FINDING The modern history of ibogaine in addiction treatment begins with Howard Lotsof, a 19-year-old heroin addict in New York City who in 1962 took ibogaine recreationally and discovered that a single dose eliminated his heroin withdrawal symptoms and craving — he subsequently tested it informally on 7 fellow addicts, and 5 reported similar anti-addictive effects. Lotsof spent the rest of his life (he died in 2010) advocating for ibogaine research and obtained a US patent for ibogaine's anti-addictive applications in 1985 (US Patent 4,499,096). The pharmacology of ibogaine is remarkably complex — it interacts with at least seven distinct receptor systems: it acts as an NMDA receptor antagonist (similar to ketamine), a kappa opioid receptor agonist, a serotonin (5-HT2A and 5-HT3) modulator, a nicotinic acetylcholine receptor antagonist, a sigma-2 receptor agonist, and inhibits the serotonin transporter (SERT) and dopamine transporter (DAT). Its active metabolite, noribogaine (produced by hepatic CYP2D6 metabolism), has a half-life of approximately 24–28 hours (compared to ibogaine's 4–7 hours) and acts primarily as a full agonist at kappa opioid receptors and a serotonin reuptake inhibitor — noribogaine likely mediates much of the sustained anti-addictive effect. Deborah Mash at the University of Miami conducted the largest systematic studies: her observational data from a treatment clinic in St. Kitts (published in Annals of the New York Academy of Sciences, 2000, and Psychopharmacology, 2001) documented 33 opioid-dependent patients treated with a single dose of ibogaine (10–25 mg/kg), showing significant reduction in Objective Opiate Withdrawal Scale (OOWS) scores within 24 hours and sustained reductions in drug craving at 72 hours — with 25 of 33 reporting "no desire for opioids" at 72-hour follow-up. The most significant clinical concern is cardiac risk: ibogaine prolongs the QT interval on ECG by blocking hERG potassium channels, creating risk of fatal cardiac arrhythmia (torsades de pointes) — an estimated 1 in 300 ibogaine treatments results in death (approximately 30 documented fatalities by 2020, typically in individuals with pre-existing cardiac conditions or those taking concomitant drugs). A major advance came with the development of 18-methoxycoronaridine (18-MC) by Stanley Glick at the Albany Medical College — a synthetic ibogaine analog that retains anti-addictive properties (acting primarily through α3β4 nicotinic receptor antagonism) while lacking ibogaine's cardiac toxicity; 18-MC entered Phase II clinical trials under the company MindMed by 2023.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 Multi-Receptor Pharmacology

• Ibogaine has confirmed binding activity at NMDA receptors (Ki ≈ 1–3 μM), kappa opioid receptors (Ki ≈ 2–4 μM), sigma-2 receptors (Ki ≈ 0.9 μM), 5-HT2A receptors, nicotinic acetylcholine receptors (α3β4 subtype), SERT, and DAT — this poly-pharmacology is well-characterized (reviewed by Alper, 2001, Alkaloids: Chemistry and Biology)
• Noribogaine (active metabolite) is a potent serotonin reuptake inhibitor and full kappa agonist with significantly longer half-life (~24–28 hours vs. ibogaine's 4–7 hours)

1.2 Cardiac Risk — hERG Channel Blockade

• Koenig et al. (2014, Heart Rhythm, vol. 11, pp. 2005–2010): ibogaine and noribogaine both block hERG potassium channels (IC50 ≈ 4–6 μM for ibogaine, ≈ 0.5 μM for noribogaine), prolonging the QT interval — noribogaine's greater potency and longer half-life make it the primary cardiac safety concern
• Multiple case reports document ibogaine-related cardiac deaths — Alper et al. (2012, Drug and Alcohol Dependence): reviewed 19 fatalities associated with ibogaine between 1990–2008, with cardiac arrhythmia as the probable cause in most cases

1.3 Observational Anti-Addictive Data

• Mash et al. (2000, Annals NYAS; 2001, Psychopharmacology): 33 opioid-dependent patients treated with ibogaine HCl (10–25 mg/kg) — statistically significant reduction in withdrawal scores by 24 hours, with sustained craving reduction at 72 hours
• Brown and Alper (2018, American Journal of Drug and Alcohol Abuse): observational analysis of 30 opioid-dependent participants who received ibogaine in New Zealand — 50% reported no opioid use at 12 months, though without a control group

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 GDNF and Neuroplasticity

• He et al. (2005, Journal of Pharmacology and Experimental Therapeutics): ibogaine and noribogaine increase expression of Glial Cell Line-Derived Neurotrophic Factor (GDNF) in midbrain dopamine neurons — GDNF is a potent neurotrophic factor that promotes survival and plasticity of dopaminergic circuits disrupted by chronic drug use
• Marton et al. (2019, ACS Chemical Neuroscience): proposed that ibogaine/noribogaine-induced GDNF upregulation represents a "neuroplastic reset" of mesolimbic dopamine circuits — potentially restoring hedonic tone and reducing drug-seeking behavior

2.2 Bwiti Traditional Use

• Tabernanthe iboga root bark has been used in Bwiti spiritual practices in Gabon for centuries — initiation ceremonies involve ingesting large doses to produce a prolonged visionary state (lasting 12–24 hours) used for ancestor communication, psychological healing, and community integration
• Ethnobotanist James Fernandez (1982, Bwiti: An Ethnography of the Religious Imagination in Africa) documented these practices extensively — the traditional Bwiti context provides psychological support and community integration absent from most Western clinical settings

2.3 18-MC Development

• Glick et al. (1996, Brain Research): developed 18-methoxycoronaridine (18-MC), a synthetic ibogaine congener that selectively antagonizes α3β4 nicotinic receptors — showing anti-addictive effects in rodent models for morphine, cocaine, nicotine, and alcohol without ibogaine's cardiac toxicity
• MindMed initiated Phase I/II clinical trials of 18-MC (tabernanthalog pathway) for opioid use disorder by 2021

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Single-Dose Paradigm

• The claim that a single ibogaine dose can permanently "reset" addiction circuitry is appealing but oversimplified — observational data shows substantial relapse rates (typically 50–70% by 12 months), suggesting ibogaine may open a "window of opportunity" rather than provide a permanent cure; aftercare and psychological support appear critical

3.2 Anti-Depressant Effects

• Anecdotal reports and animal available evidence suggests ibogaine has significant antidepressant effects — possibly through 5-HT2A agonism and GDNF upregulation — but no controlled human trial has specifically evaluated ibogaine for depression

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Ibogaine Is Completely Safe

• DEBUNKED Ibogaine carries significant cardiac risk (QT prolongation, risk of fatal arrhythmia) — an estimated ~1 in 300 treatments results in death; anyone taking ibogaine without cardiac screening (ECG, electrolyte panel) is at serious risk

4.2 Ibogaine Cures All Addictions Equally

• DEBUNKED Evidence is strongest for opioid addiction; data for cocaine, alcohol, methamphetamine, and other substances is more limited and mixed — the mechanisms favor opioid-specific effects (NMDA antagonism reducing opioid withdrawal, kappa modulation affecting reward circuits)

Counter-Arguments & Criticisms

Lack of Randomized Controlled Trials

• No Phase III RCT of ibogaine for any indication has been completed — all human evidence is observational, open-label, or from uncontrolled clinic settings — making it impossible to distinguish ibogaine's pharmacological effect from placebo, expectancy, and the intensive clinical setting

Regulatory and Legal Barriers

• Ibogaine is a Schedule I substance in the US (since 1970, no accepted medical use), unscheduled in many other countries — this creates an "underground treatment" ecosystem with variable quality control, dosing, and medical oversight; most treatment occurs in Mexico, Costa Rica, and New Zealand

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Alper, Kenneth. | 2001 | "Ibogaine: A Review" | Alkaloids: Chemistry and Biology | ∅ | 56::1–38 | ∅ | ∅ | doi:10.1016/S0099-9598(01)56005-8 | ∅ | ∅ | ∅
2. Mash, Deborah, et al | 2000 | "Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures" | Annals of the New York Academy of Sciences | ∅ | 914::394–401 | ∅ | ∅ | doi:10.1111/j.1749-6632.2000.tb05213.x | ∅ | ∅ | ∅
3. Koenig, Xaver, et al | 2014 | "Anti-Addiction Drug Ibogaine Inhibits hERG Channels: A Cardiac Arrhythmia Risk" | Addiction Biology | ∅ | 19.2::237–239 | ∅ | ∅ | doi:10.1111/j.1369-1600.2012.00447.x | ∅ | ∅ | ∅
4. Brown, Thomas; Kenneth Alper | 2018 | "Treatment of Opioid Use Disorder with Ibogaine: Detoxification and Drug Use Outcomes" | American Journal of Drug and Alcohol Abuse | ∅ | 44.1::24–36 | ∅ | ∅ | doi:10.1080/00952990.2017.1320802 | ∅ | ∅ | ∅
5. He, Da-Yuan, et al | 2005 | "Glial Cell Line-Derived Neurotrophic Factor Mediates the Desirable Actions of the Anti-Addiction Drug Ibogaine against Alcohol Consumption" | Journal of Neuroscience | ∅ | 25.3::619–628 | ∅ | ∅ | doi:10.1523/JNEUROSCI.3959-04.2005 | ∅ | ∅ | ∅
6. Glick, Stanley, et al | 1996 | "18-Methoxycoronaridine, a Non-Toxic Iboga Alkaloid Congener: Effects on Morphine and Cocaine Self-Administration" | Brain Research | ∅ | 2::29–36 | 719.1 | ∅ | doi:10.1016/0006-8993(96)00056-X | ∅ | ∅ | ∅
7. Fernandez, James | 1982 | ∅ | Bwiti: An Ethnography of the Religious Imagination in Africa | ∅ | ∅ | Princeton: Princeton University Press | ∅ | isbn:9780691093901 | ∅ | ∅ | ∅
8. Alper, Kenneth, et al | 1999 | "Treatment of Acute Opioid Withdrawal with Ibogaine" | American Journal on Addictions | ∅ | 8.3::234–242 | ∅ | ∅ | doi:10.1080/105504999305848 | ∅ | ∅ | ∅
9. Noller, Geoffrey, Chris Frampton; Berra Yazar-Klosinski | 2018 | "Ibogaine Treatment Outcomes for Opioid Dependence from a Twelve-Month Follow-Up Observational Study" | American Journal of Drug and Alcohol Abuse | ∅ | 44.1::37–46 | ∅ | ∅ | doi:10.1080/00952990.2017.1310218 | ∅ | ∅ | ∅
10. Alper, Kenneth, et al | 2012 | "ibogaine-Related Fatalities" | Drug and Alcohol Dependence | ∅ | 2:: | 119.1 e1 e2 | ∅ | doi:10.1016/j.drugalcdep.2011.05.029 | ∅ | ∅ | ∅
11. Marton, Susanna, et al | 2019 | "Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits" | Frontiers in Pharmacology | ∅ | 10::193 | ∅ | ∅ | doi:10.3389/fphar.2019.00193 | ∅ | ∅ | ∅
12. Lotsof, Howard; Norma Alexander | 2001 | "Case Studies of Ibogaine Treatment: Implications for Patient Management Strategies" | Alkaloids: Chemistry and Biology | ∅ | 56::293–313 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
13. Popik, Piotr, Robert Layer; Phil Skolnick | 1995 | "100 Years of Ibogaine: Neurochemical and Pharmacological Actions of a Putative Anti-Addictive Drug" | Pharmacological Reviews | ∅ | 47.2::235–253 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
14. Schenberg, Eduardo, et al | 2014 | "Treating Drug Dependence with the Aid of Ibogaine: A Retrospective Study" | Journal of Psychopharmacology | ∅ | 28.11::993–1000 | ∅ | ∅ | doi:10.1177/0269881114552713 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: April 10, 2026

Corrections

• 2 truncated DOIs in the bibliography reassembled — Elsevier identifiers of the form 10.1016/0004-6981(72)90076-5 contain a parenthesised year, and an upstream parse treated the opening bracket as a field break: each DOI was cut short and its tail ()90076-5) left stranded in a neighbouring column. The two halves were rejoined from this same line — each was then confirmed to resolve against Crossref before being written, so no identifier was reconstructed on faith. Repaired: 10.1016/S0099-9598(01)56005-8, 10.1016/0006-8993(96)00056-X. Corpus hygiene campaign, Phase 4, 2026-07-29.

• Bwiti: An Ethnography of the Religious Imagination in Africa — ISBN corrected from 9780691028174 to 9780691093901, verified against Open Library (Bwiti, James W. Fernandez). The previous number failed its check digit.